More than half of cancer cases occur in patients aged 65 years or older. The efficacy and safety of antibody drug conjugates (ADCs) in older patients remains an unclear subject as available evidence is limited. Geriatric population is underrepresented in clinical trials. Consequently, most of our knowledge regarding innovative therapeutics was studied on a younger population. In this review of published literature, we report the available information on efficacy, safety and pharmacokinetics of FDA approved ADCs for hematologic malignancies and solid tumors in the geriatric population. We explore the results of clinical trials dedicated for older individuals as well as subgroup analyses of the geriatric population in major trials evaluating these drugs. Available data suggest a similar efficacy in older adults as compared to general population. However, older patients might be prone to a higher rate of adverse events in incidence with a potential impact on quality of life. We lack data to support primary dose reductions or schedule modifications in this category of patients. No pharmacokinetic differences were reported between age groups. It is crucial to encourage the development of clinical trials dedicated to older patients with geriatric parameters (G8 score, G-CODE...) so that results can be more representative of this population outside of clinical trials.
Antibody drug conjugates in older patients: State of the art / Rached, Layal; Geraud, Arthur; Frelaut, Maxime; Ap Thomas, Zoe; Goldschmidt, Vincent; Beraud-Chaulet, Geoffroy; Nagera-Lazarovici, Celine; Danlos, Francois-Xavier; Henon, Clemence; Parisi, Claudia; Gazzah, Anas; Bahleda, Rastilav; Postel Vinay, Sophie; Smolenschi, Cristina; Hollebecque, Antoine; Michot, Jean-Marie; Ribrag, Vincent; Loriot, Yohann; Champiat, Stephane; Ouali, Kaissa; Massard, Christophe; Ponce Aix, Santiago; Bringuier, Michael; Baldini, Capucine. - In: CRITICAL REVIEWS IN ONCOLOGY/HEMATOLOGY. - ISSN 1879-0461. - 193:(2024). [10.1016/j.critrevonc.2023.104212]
Antibody drug conjugates in older patients: State of the art
Parisi, ClaudiaValidation
;
2024
Abstract
More than half of cancer cases occur in patients aged 65 years or older. The efficacy and safety of antibody drug conjugates (ADCs) in older patients remains an unclear subject as available evidence is limited. Geriatric population is underrepresented in clinical trials. Consequently, most of our knowledge regarding innovative therapeutics was studied on a younger population. In this review of published literature, we report the available information on efficacy, safety and pharmacokinetics of FDA approved ADCs for hematologic malignancies and solid tumors in the geriatric population. We explore the results of clinical trials dedicated for older individuals as well as subgroup analyses of the geriatric population in major trials evaluating these drugs. Available data suggest a similar efficacy in older adults as compared to general population. However, older patients might be prone to a higher rate of adverse events in incidence with a potential impact on quality of life. We lack data to support primary dose reductions or schedule modifications in this category of patients. No pharmacokinetic differences were reported between age groups. It is crucial to encourage the development of clinical trials dedicated to older patients with geriatric parameters (G8 score, G-CODE...) so that results can be more representative of this population outside of clinical trials.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
